Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:mesalamine
go back to main search page
Accession:CHEBI:6775 term browser browse the term
Definition:A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Synonyms:exact_synonym: 5-amino-2-hydroxybenzoic acid
 related_synonym: 3-carboxy-4-hydroxyaniline;   5-ASA;   5-Aminosalicylic acid;   Asacol;   Asacolitin;   Canasa;   Claversal;   Fisalamine;   Formula=C7H7NO3;   Iialda;   InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11);   InChIKey=KBOPZPXVLCULAV-UHFFFAOYSA-N;   Lixacol;   Mesalazina;   Mesalazinum;   Mesasal;   Pentasa;   Rowasa;   SMILES=Nc1ccc(O)c(c1)C(O)=O;   Salofalk;   m-Aminosalicylic acid;   mesalazine;   p-Aminosalicylsaeure
 xref: Beilstein:2090421;   CAS:89-57-6;   DrugBank:DB00244;   Drug_Central:1710;   HMDB:HMDB0014389;   KEGG:D00377;   LINCS:LSM-5427
 xref_mesh: MESH:D019804
 xref: MetaCyc:CPD-12711;   PMID:10648473;   PMID:22304735;   PMID:22648999;   PMID:23137838;   PMID:23146664;   PMID:23302220;   PMID:28166217;   Reaxys:2090421;   Wikipedia:Mesalamine
 cyclic_relationship: is_conjugate_acid_of CHEBI:20551


show annotations for term's descendants           Sort by:
 
mesalamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions EXP Mesalamine inhibits the reaction [Thioacetamide results in increased expression of ACTA2 protein] CTD PMID:29738702 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Alb albumin multiple interactions EXP Mesalamine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] CTD PMID:29738702 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Arrb1 arrestin, beta 1 multiple interactions EXP Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ARRB1 protein] CTD PMID:24637189 NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Mesalamine inhibits the reaction [Acetic Acid results in increased expression of BAX mRNA] CTD PMID:29518435 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Mesalamine inhibits the reaction [Acetic Acid results in decreased expression of BCL2 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BCL2 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BCL2 protein] CTD PMID:24637189, PMID:29518435 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Casp3 caspase 3 multiple interactions EXP Mesalamine inhibits the reaction [Acetic Acid results in increased expression of CASP3 mRNA]; Mesalamine inhibits the reaction [Thioacetamide affects the expression of CASP3 protein] CTD PMID:29518435, PMID:29738702 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl20 C-C motif chemokine ligand 20 multiple interactions ISO [Mesalamine co-treated with Glucocorticoids] results in decreased expression of CCL20 mRNA; Mesalamine results in decreased expression of [IL1B protein results in increased expression of CCL20 protein]; Mesalamine results in decreased expression of [TNF protein results in increased expression of CCL20 protein] CTD PMID:16306769 NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases secretion ISO Mesalamine results in increased secretion of CXCL1 protein CTD PMID:12231210 NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 increases secretion ISO Mesalamine results in increased secretion of CXCL1 protein CTD PMID:12231210 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of GCLC mRNA CTD PMID:27818126 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA] CTD PMID:27818126 NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP Mesalamine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] CTD PMID:29738702 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with resveratrol] results in increased expression of HMOX1 mRNA] CTD PMID:27818126 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Ifng interferon gamma multiple interactions ISO [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of GCLC mRNA; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin 3-O-glucoside] results in increased expression of PPARG protein]; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with resveratrol] results in increased expression of HMOX1 mRNA]; Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA] CTD PMID:27818126 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of GCLC mRNA; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin 3-O-glucoside] results in increased expression of PPARG protein]; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with resveratrol] results in increased expression of HMOX1 mRNA]; Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA] CTD PMID:27818126 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1b interleukin 1 beta increases expression
multiple interactions
ISO
EXP
Mesalamine results in increased expression of IL1B mRNA
[allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]; [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Acetic Acid results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]
Mesalamine results in decreased expression of [IL1B protein results in increased expression of CCL20 protein]
CTD PMID:10743803, PMID:16306769, PMID:25729217, PMID:29518435 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il2 interleukin 2 multiple interactions ISO Mesalamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 protein] CTD PMID:7815356 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il2ra interleukin 2 receptor subunit alpha multiple interactions ISO Mesalamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2RA protein] CTD PMID:7815356 NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
JBrowse link
G Il4 interleukin 4 multiple interactions EXP [allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased secretion of IL4 protein] CTD PMID:25729217 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions EXP Mesalamine inhibits the reaction [Acetic Acid results in increased expression of MAPK14 mRNA] CTD PMID:29518435 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO
EXP
Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
Mesalamine inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
CTD PMID:25079872, PMID:29518435, PMID:30365937 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nat1 N-acetyltransferase 1 increases acetylation ISO NAT1 protein results in increased acetylation of Mesalamine CTD PMID:15627487 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573
JBrowse link
G Nat2 N-acetyltransferase 2 increases acetylation ISO NAT2 protein results in increased acetylation of Mesalamine CTD PMID:15627487 NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions ISO [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein CTD PMID:27818126 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP Mesalamine inhibits the reaction [Acetic Acid results in increased expression of NOS2 mRNA] CTD PMID:29518435 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Oprd1 opioid receptor, delta 1 multiple interactions EXP Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of OPRD1 mRNA]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of OPRD1 protein] CTD PMID:24637189 NCBI chr 5:150,288,126...150,323,063
Ensembl chr 5:150,288,126...150,323,063
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage ISO Mesalamine results in increased cleavage of PARP1 protein CTD PMID:12663503 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin 3-O-glucoside] results in increased expression of PPARG protein] CTD PMID:27818126 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP Mesalamine inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein] CTD PMID:29518435 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Slco1b2 solute carrier organic anion transporter family member 1B2 increases uptake
multiple interactions
ISO SLCO1B3 protein results in increased uptake of Mesalamine
Budesonide inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Cyclosporine inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]
CTD PMID:21430235 NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
JBrowse link
G Slco2b1 solute carrier organic anion transporter family, member 2b1 multiple interactions
increases uptake
ISO Budesonide inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Cyclosporine inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine] CTD PMID:21430235 NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP Mesalamine inhibits the reaction [Thioacetamide results in increased expression of SPP1 protein] CTD PMID:29738702 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP Mesalamine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 protein] CTD PMID:29738702 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 increases expression ISO Mesalamine results in increased expression of TIMP2 mRNA CTD PMID:10743803 NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO
EXP
[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased activity of NFE2L2 protein; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of GCLC mRNA; [IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with Mesalamine] results in increased expression of PPARG protein; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with cyanidin 3-O-glucoside] results in increased expression of PPARG protein]; Mesalamine inhibits the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein co-treated with resveratrol] results in increased expression of HMOX1 mRNA]; Mesalamine promotes the reaction [[IL1A protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of GCLM mRNA]; Mesalamine promotes the reaction [Endotoxins results in increased expression of TNF protein]; Mesalamine results in decreased expression of [TNF protein results in increased expression of CCL20 protein]
[allicin co-treated with Mesalamine] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Thioacetamide results in increased expression of TNF protein]; Mesalamine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]
CTD PMID:7496871, PMID:16306769, PMID:25729217, PMID:27818126, PMID:29518435, PMID:29738702 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tpm3 tropomyosin 3 decreases expression ISO Mesalamine results in decreased expression of TPM3 mRNA alternative form; Mesalamine results in decreased expression of TPM3 protein alternative form CTD PMID:19369484 NCBI chr 2:189,423,534...189,451,340
Ensembl chr 2:189,423,559...189,451,029
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions EXP Mesalamine inhibits the reaction [Acetic Acid results in increased expression of VEGFA mRNA] CTD PMID:29518435 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19810
    role 19758
      biological role 19758
        antimicrobial agent 17329
          antifungal agent 14912
            salicylic acid 741
              mesalamine 37
Path 2
Term Annotations click to browse term
  CHEBI ontology 19810
    subatomic particle 19808
      composite particle 19808
        hadron 19808
          baryon 19808
            nucleon 19808
              atomic nucleus 19808
                atom 19808
                  main group element atom 19696
                    p-block element atom 19696
                      carbon group element atom 19599
                        carbon atom 19588
                          organic molecular entity 19588
                            organic group 18527
                              organic divalent group 18520
                                organodiyl group 18520
                                  carbonyl group 18427
                                    carbonyl compound 18427
                                      carboxylic acid 18108
                                        aromatic carboxylic acid 10901
                                          benzoic acids 10870
                                            benzoic acid 3841
                                              hydroxybenzoic acid 3231
                                                monohydroxybenzoic acid 1266
                                                  salicylic acid 741
                                                    mesalamine 37
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.